IP Verse

Method And Composition For Treating Ocular Hypertension And Glaucoma - EP3714877

The patent EP3714877 was granted to AGC on Jan 26, 2022. The application was originally filed on May 28, 2009 under application number EP20164602A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3714877

AGC
Application Number
EP20164602A
Filing Date
May 28, 2009
Status
Granted And Under Opposition
Dec 24, 2021
Grant Date
Jan 26, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (3)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

BECKEROct 26, 2022BECKER KURIG & PARTNER PATENTANWALTE MBBWITHDRAWN
DE GREGORIOct 26, 2022-WITHDRAWN
COOKEOct 25, 2022ELKINGTON AND FIFEADMISSIBLE

Patent Citations (37) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0850926
DESCRIPTIONEP0969846
DESCRIPTIONEP1011728
DESCRIPTIONEP1115406
DESCRIPTIONEP1321144
DESCRIPTIONEP1349580
DESCRIPTIONEP1547599
DESCRIPTIONEP1666043
DESCRIPTIONEP1825855
DESCRIPTIONEP1829545
DESCRIPTIONEP1905453
DESCRIPTIONEP1916002
DESCRIPTIONUS2007248697
DESCRIPTIONUS5409125
DESCRIPTIONUS5614172
DESCRIPTIONUS5807892
DESCRIPTIONUS5886035
DESCRIPTIONUS6096783
DESCRIPTIONUS6241124
DESCRIPTIONUS6344477
DESCRIPTIONWO2007042262
OPPOSITIONEP1011728
OPPOSITIONEP1321144
OPPOSITIONEP1825855
OPPOSITIONEP1825955
OPPOSITIONEP2127638
OPPOSITIONEP2772249
OPPOSITIONEP3205334
OPPOSITIONUS2005287325
OPPOSITIONUS2006108384
OPPOSITIONUS6241124
OPPOSITIONUS9999593
OPPOSITIONWO0003736
OPPOSITIONWO2009145356
SEARCHEP1321144
SEARCHEP1825855
SEARCHWO0003736

Non-Patent Literature (NPL) Citations (40) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "Decentralised Procedure Public Assessment Report: Taflotan 15 micrograms/mL eye drops, solution, and solution, single dose container", BfArM, (20080319), BfArM, (20221108), XP055978702-
OPPOSITION- Anonymous, "Ganfort. Procedural steps and scientific information after the authorisation", EMA, (20170406), pages 1 - 8, EMA, (20221109), XP055979487-
OPPOSITION- Anonymous, "Ganfort SmPC", (20060623), URL: https://ec.europa.eu/health/documents/community-resgister/html/h340.htm, (20221108), XP055978703-
OPPOSITION- Anonymous, "GUIDELINE ON THE CATEGORISATION OF EXTENSION APPLICATIONS (EA) versus VARIATIONS APPLICATIONS (V)", European Commission, (20031001), pages 1 - 10, XP055775088-
OPPOSITION- Anonymous, "LUMIGAN SMPC", (20020101), (20221107), XP055978694-
OPPOSITION- Anonymous, "Paper-based flexible packaging ", Anonymous, M.J. Kirwan, Paper and Paperboard Packaging Technology, London UK, Blackwell Publishing Ltd, (20050101), pages 106 - 107, ISBN 978-1-4051-2503-1, XP093128431-
OPPOSITION- Anonymous, "PRESERVATIVE-FREE STERILE OPHTHALMIC SOLUTION in a Sterile Ophthalmic Unit Dose Dispenser TIMOPTIC® SMPC", Merck and Co., (20050101), Merck and Co., (20221107), XP055978700-
OPPOSITION- Anonymous, "Raw Materials , processing and properties ", Anonymous, M.J. Kirwan, Paper and Paperboard Packaging Technology, London UK, Blackwell Publishing Ltd, (20050101), pages 21 - 26, ISBN 978-1-4051-2503-1, XP093128423-
OPPOSITION- Anonymous, "Saflutan 15 micrograms/ml eye drops, solution, in a single-dose container", Summary of Product Characteristics (SmPC) of medicinal product, (20201222), pages 1 - 6, Summary of Product Characteristics (SmPC) of medicinal product , URL: https://www.medicines.org.uk, (20221109), XP055979496-
OPPOSITION- Anonymous, "Santen Oy Receives Marketing Authorization for its Glaucoma and Ocular Hypertension Treatment, TAFLOTAN TM in Denmark", Santen - News Release, (20080507), Santen - News Release, URL: https://www.santen.com/en/news/20080507.pdf, (20221109), XP055979507-
OPPOSITION- Anonymous, "Scientific Discussion (Ganfort)", EMEA, (20060101), pages 1 - 37, XP055629311-
OPPOSITION- Anonymous, "Summary of Product Characteristics Taptiqom 15 micrograms/ml + 5 mg/ml eye drops, solution in single-dose container.", Santen UK Limited, (20180201), pages 1 - 9, XP055775092-
OPPOSITION- Anonymous, "TIMOPTIC® ", Merck - Data Sheet, (20050101), pages 1 - 7, Merck - Data Sheet, URL: https://www.merck.com, (20221109), XP055979445-
OPPOSITION- Anonymous, "Traviop 40 microgrammi/ml collirio, soluzione in a single-dose container", Summary of Product Characteristics (SmPC), (20200901), Summary of Product Characteristics (SmPC), (20221109), XP055979514-
OPPOSITION- Anonymous, " Xalacom eye drops, solution -Summary of Product Characteristics (SmPC)", Xalacom, (20110101), Xalacom, (20221107), XP055978692-
OPPOSITION- Anonymous, "Zusammenfassung der merkmale des arzneimittels", Taflotan SmPC, (20210101), Taflotan SmPC, (20221107), XP055978691-
OPPOSITION- E J Higginbotham, Diestelhorst M, Pfeiffer N, Rouland J F, Alm A, "The Efficacy and Safety of Unfixed and Fixed Combinations of Latanoprost and Other Antiglaucoma Medications", Surv Ophthalmol, (20020801), vol. 47, no. Suppl.1, pages S133 - S140, XP055461693-
OPPOSITION- Evgeny Egorov; Auli Ropo, "Adjunctive use of tafluprost with timolol provides additive effects for reduction in intraocular pressure in patients with glaucoma /Abstract/", Acta Ophthalmologica, (20070901), pages 1 - 2, XP055462093-
OPPOSITION- Evgeny Egorov, Auli Ropo, "Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma", EUROPEAN JOURNAL OF OPHTHALMOLOGY, Wichtig Publishing, IT, IT , (20090301), vol. 19, no. 2, ISSN 1120-6721, pages 214 - 222, XP008142945-
OPPOSITION- HAMACHER T. et al., "Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis", Acta Ophthalmol., (20080000), vol. 86, no. S242, pages 14 - 19, XP055974472-
OPPOSITION- HIGGINBOTHAM, E. J. et al., "The Efficacy and Safety of Unfixed and Fixed Combinations of Latanoprost and Other Antiglaucoma Medications", Surv Ophthalmol., (20020000), vol. 47, no. S1, pages s133 - s140, XP055461693-
OPPOSITION- Lichtenstein, "Blow-Fill-Seal for Ophthalmie Packaging", Innovations in Pharmaceutical Technology, (20070101), pages 122 - 123, XP055788646-
OPPOSITION- Merck & Co., Inc., "PRESERVATIVE-FREE STERILE OPHTHALMIC SOLUTION in a Sterile Ophthalmic Unit Dose Dispenser TIMOPTIC® 0.25% AND 0.5% (TIMOLOL MALEATE OPHTHALMIC SOLUTION) in OCUDOSE® (DISPENSER)", Data Sheet, (20050701), pages 1 - 7, XP055462098-
OPPOSITION- Tga, "Australian Public Assessment Report for Tafluprost", Australian Government. Therapeutic Goods Administration, (20120503), pages 1 - 86, Australian Government. Therapeutic Goods Administration, URL: https://www.health.gov.au, (20221109), XP055979508-
OPPOSITION- UUSITALO H. et al., "Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers", Acta Ophthalmol., (20080000), vol. 86, no. S242, pages 7 - 13, XP055974481-
OPPOSITION- World Health Organization, "General requirements for dosage forms Ophthamic preparations", The International Pharmacopoeia THIRD EDITION, Volume 5, Geneva , World Health Organization , (20030101), pages 7 - 11, XP055775213-
OPPOSITION- Schuman, J.S. et al, "Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension", American Journal of Ophthalmology, AMSTERDAM, NL , (20050801), vol. 140, no. 2, doi:10.1016/j.ajo.2005.02.058, ISSN 0002-9394, pages 242.e1 - 242.e, XP005010648
OPPOSITION- Schuman, J.S. Katz, G.J. Lewis, R.A. Henry, J.C. Mallick, S. Wells, D.T. Sullivan, E.K. Landry, T.A. Bergamini, M.V.W. Robertson, S.M., "Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20050801), vol. 140, no. 2, doi:10.1016/j.ajo.2005.02.058, ISSN 0002-9394, pages 242.e1 - 242.e11, XP005097402
OPPOSITION- Schuman, J.S. Katz, G.J. Lewis, R.A. Henry, J.C. Mallick, S. Wells, D.T. Sullivan, E.K. Landry, T.A. Bergamini, M.V.W. Robertson, S.M., "Efficacy and Safety of a Fixed Combination of Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution Once Daily for Open-Angle Glaucoma or Ocular Hypertension", American Journal of Ophthalmology, Elsevier, AMSTERDAM, NL, AMSTERDAM, NL , (20050801), vol. 140, no. 2, doi:10.1016/j.ajo.2005.02.058, ISSN 0002-9394, pages 242.e1 - 242.e, XP005010648
OPPOSITION- BRASNU E. et al., "In Vitro effects of preservative-free Tafluprost and Preserved Latanoprost, Travoprost, and Bimatoprost in a Conjunctival Epithelial Cell Line", Current Eye Research, (20080000), vol. 33, doi:10.1080/02713680801971857, pages 303 - 312, XP009108708
OPPOSITION- BRASNU E et al., "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (20080400), vol. 33, no. 4, pages 303 - 312, XP009108708
OPPOSITION- BRASNU E et al., "In vitro effects of preservative- free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (20080404), vol. 33, pages 303 - 312, XP009108708
OPPOSITION- Ishida Naruhiro, Odani-Kawabata Noriko, Shimazaki Atsushi, Hara Hideaki, "Prostanoids in the Therapy of Glaucoma", CARDIOVASCULAR DRUG REVIEWS, NEVA PRESS, BRANFORD, CT, US, US , (20060301), vol. 24, no. 1, doi:10.1111/j.1527-3466.2006.00001.x, ISSN 0897-5957, pages 1 - 10, XP055978698
OPPOSITION- Thygesen John, "In search of improved prostaglandin treatment for glaucoma", Acta Ophthalmologica: the ophthalmological journal of the Nordic countries, Wiley-Blackwell Munksgaard, Denmark, Denmark , (20080901), vol. 86, doi:10.1111/j.1755-3768.2008.01379.x, ISSN 1755-375X, pages 5 - 6, XP055978697
OPPOSITION- Kuppens E V; de Jong C A; Stolwijk T R; de Keizer R J; van Best J A, "Effect of timolol with and without preservative on the basal tear turnover in glaucoma.", BRITISH JOURNAL OF OPHTHALMOLOGY, BMJ Publishing Group, GB, GB , (19950401), vol. 79, no. 4, doi:10.1136/bjo.79.4.339, ISSN 0007-1161, pages 339 - 342, XP009108698
OPPOSITION- KUPPENS E V M et al., "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, (19950000), vol. 79, doi:10.1136/bjo.79.4.339, pages 339 - 342, XP009108698
OPPOSITION- PISELLA P. J. et al., "Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication", Br. J. Ophthalmol., (20020000), vol. 86, doi:10.1136/bjo.86.4.418, pages 418 - 423, XP055629318
OPPOSITION- Ota Takashi, Murata Hiroshi, Sugimoto Ei-Ichiro, Aihara Makoto, Araie Makoto, "Prostaglandin Analogues and Mouse Intraocular Pressure: Effects of Tafluprost, Latanoprost, Travoprost, and Unoprostone, Considering 24-Hour Variation", Investigative Opthalmology & Visual Science, Association for Research in Vision and Ophthalmology, US, US , (20050601), vol. 46, no. 6, doi:10.1167/iovs.04-1527, ISSN 1552-5783, page 2006, XP055978701
SEARCH- BRASNU E ET AL., "In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line", CURRENT EYE RESEARCH, (200804), vol. 33, no. 4, pages 303 - 312, XP009108708 [A] 1-10 * the whole document *
SEARCH- KUPPENS E V M ET AL., "Effect of timolol with and without preservative on the basal tear turnover in glaucoma", BRITISH JOURNAL OF OPHTHALMOLOGY, (1995), vol. 79, pages 339 - 342, XP009108698 [A] 1-10 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents